Use of omalizumab in the treatment of food allergy and anaphylaxis

Current Allergy and Asthma Reports

Volumn 13, Issue 1, 2013, Pages 78-84

  Lieberman, Jay A ^a   Chehade, Mirna ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anaphylaxis; Anti IgE; Eosinophilic gastrointestinal diseases; Food allergy; IgE; IgE mediated food allergy; Immunotherapy; Omalizumab; Peanut allergy; Treatment

Indexed keywords

ADRENALIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOMODULATING AGENT; OMALIZUMAB; PLACEBO; TALIZUMAB;

ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; ASTHMA; BINDING AFFINITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIC GASTROINTESTINAL DISORDER; FOOD ALLERGY; HUMAN; IDIOPATHIC ANAPHYLAXIS; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOTHERAPY; MASTOCYTOSIS; PEANUT ALLERGY; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; FOOD HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY;

EID: 84872608684     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0316-x     Document Type: Article

References (45)

1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-6. (Pubitemid 38608590)
2. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol. 2006;117:391-7. (Pubitemid 43190153)
3. Lieberman PL, et al. Anaphylaxis. In: Adkinson NF, editor. Middleton's allergy: principles and practice. 7th ed. Philadelphia: Mosby Elsevier; 2009. p. 1027-51.
4. • Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125:S161-81. Comprehensive review of anaphylaxis: pathogenesis, diagnosis and management.
5. Brownwell J, Casale TB. Anti-IgE therapy. Immunol Allergy Clin North Am. 2004;24:551-68. (Pubitemid 39330307)
6. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-E monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474-82.
7. MacGlashan Jr DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-45. (Pubitemid 127469971)
8. Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med 2012 Aug 9 [Epub ahead of print].
9. MacGlashan Jr DW, Bochner BS, Adelman DC, et al. Serum IgE level drives basophil and mast cell IgE receptor display. Int Arch Allergy Immunol. 1997;113:45-7. (Pubitemid 27160716)
10. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol. 2004;114:527-30. (Pubitemid 39194924)
11. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-93. (Pubitemid 39202198)
12. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113:297-302. (Pubitemid 38210553)
13. Gomez G, Jogie-Brahim S, Shima M, Schwartz LB. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol. 2007;179:1353-61.
14. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147-54. (Pubitemid 37550008)
15. Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol. 2010;125:896-901.
16. Foster B, Foroughi S, Yin Y, Prussin C. Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders. Clin Mol Allergy. 2011;9:7.
17. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol. 2008;146:66-70. (Pubitemid 351562944)
18. Eckman JA, Sterba PM, Kelly D. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol. 2010;125:889-95.
19. Savage JH, Courneya JP, Sterba PM. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012 [Epub ahead of print].
20. MacGlashan DW Jr, Savage J, Wood R, Saini S. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 2012 Jul 14 [Epub ahead of print].
21. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986-93. (Pubitemid 36302243)
22. • Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309-10. Study confirming that omalizumab can be used as a monotherapy in patients with peanut allergy.
23. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654-60.
24. Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367:233-43.
25. • Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011;127:1622-4. Pilot study demonstrating a possible role for omalizumab therapy as an adjunct to oral immunotherapy in food allergic patients.
26. Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120:594-601. (Pubitemid 47320766)
27. Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr. 2011;170:1471-4.
28. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:274-80. (Pubitemid 34158294)
29. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134-40. (Pubitemid 43017150)
30. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383-9.
31. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008;63:376-8. (Pubitemid 351224685)
32. Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009;19:225-9.
33. Jones JD, Marney Jr SR, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol. 2008;101:550-1.
34. Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102:257-8.
35. Demirturk M, Gelincik A, Colakoglu B, Dal M, Buyukozturk S. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol. 2012;39:552-4.
36. Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119:1550-1. (Pubitemid 46855867)
37. Douglass JA, Carroll K, Voskamp A, et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy. 2010;65:926-7.
38. Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol. 2010;104:537-9.
39. Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol. 2010;126:415-6.
40. Molderings GJ, Raithel M, Kratz F, et al. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med. 2011;50:611-5.
41. Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol. 2012;108:383-4.
42. Bray SM, Fajt ML, and Petrov AA. Successful treatment of exercise-induced anaphylaxis with omalizumab. Ann Allergy Asthma Immunol 2012 Aug 17 [Epub ahead of print].
43. Tartibi HM, Majmundar AR, Khan DA. Successful use of omalizumab for prevention of fire ant anaphylaxis. J Allergy Clin Immunol. 2010;126:664-5.
44. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120:1373-7. (Pubitemid 350216610)
45. Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128:210-2.